AGP Executive Report
Last update: 2 hours agoVaccine & Pharma: Valneva shared its first-half 2026 results, with €64.0M in product sales and €65.8M total revenues, reaffirming full-year guidance of €135–150M and pointing to a restructuring program expected to improve P&L and cash flow later this year; it also flagged regulatory decisions for its Lyme disease vaccine candidate in the next 12 months. Climate & Public Health: A new look at urban heat islands warns that tropical cities can’t always afford fixes like shade, green roofs, lighter surfaces, and better cooling—especially as El Niño strengthens and could push record heat, raising risks for vulnerable residents. Drug Policy & Community Health: An editorial on Mauritius’ drug crisis argues the country needs a broader strategy beyond headline arrests, stressing rule-of-law safeguards while questioning links to Réunion Island travel and the use of public resources. Food Access: A community food distribution at NYC Health + Hospitals’ Lincoln “hospital without walls” delivered over 20,000 pounds of shelf-stable goods, highlighting ongoing support for local health and nutrition needs.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
